{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:17:13Z","timestamp":1778249833948,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020333","name":"Guerbet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020333","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"DOI":"10.1007\/s00270-026-04351-4","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T18:10:15Z","timestamp":1771179015000},"page":"1035-1044","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lipiodol-Mediated Dose Enhancement in Radiation Therapy: A Phantom and In Vitro Study in Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-3389","authenticated-orcid":false,"given":"Kentaro","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenkichi","family":"Michimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Anoushiravani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Bunker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bertinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima","family":"Nabavizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel T.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-7147","authenticated-orcid":false,"given":"Khashayar","family":"Farsad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"issue":"6","key":"4351_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021.","journal-title":"J Hepatol"},{"issue":"4","key":"4351_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158(4):410\u201320. https:\/\/doi.org\/10.1001\/jamasurg.2022.7989.","journal-title":"JAMA Surg"},{"issue":"6","key":"4351_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","volume":"1","author":"YR Huo","year":"2015","unstructured":"Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis: a systematic review and meta-analysis. JAMA Oncol. 2015;1(6):756\u201365. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2189.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4351_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","journal-title":"J Hepatol"},{"issue":"3","key":"4351_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ejrad.2008.08.007","volume":"72","author":"TJ Vogl","year":"2009","unstructured":"Vogl TJ, Naguib NNN, Nour-Eldin N-EA, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009;72(3):505\u201316. https:\/\/doi.org\/10.1016\/j.ejrad.2008.08.007.","journal-title":"Eur J Radiol"},{"key":"4351_CR6","unstructured":"Guerbet LLC. Lipiodol\u00ae (ethiodized oil) injection [package insert]. US food and drug administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/009190s032lbl.pdf. Accessed 21 December 2025."},{"issue":"1","key":"4351_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/mp.12028","volume":"44","author":"D Kawahara","year":"2017","unstructured":"Kawahara D, Ozawa S, Saito A, Nishio T, Kimura T, Suzuki T, et al. Dosimetric impact of lipiodol in stereotactic body radiation therapy on liver after trans-arterial chemoembolization. Med Phys. 2017;44(1):342\u20138. https:\/\/doi.org\/10.1002\/mp.12028.","journal-title":"Med Phys"},{"issue":"6","key":"4351_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/acm2.12560","volume":"20","author":"D Kawahara","year":"2019","unstructured":"Kawahara D, Ozawa S, Kimura T, Saito A, Nakashima T, Ohno Y, et al. Photon and electron backscatter dose and energy spectrum analysis around Lipiodol using flattened and unflattened beams. J Appl Clin Med Phys. 2019;20(6):178\u201383. https:\/\/doi.org\/10.1002\/acm2.12560.","journal-title":"J Appl Clin Med Phys"},{"issue":"2","key":"4351_CR9","doi-asserted-by":"publisher","first-page":"CD012244","DOI":"10.1002\/14651858.CD012244.pub2","volume":"2","author":"L Lu","year":"2019","unstructured":"Lu L, Zeng J, Wen Z, Tang C, Xu N. Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults. Cochrane Database Syst Rev. 2019;2(2):CD012244. https:\/\/doi.org\/10.1002\/14651858.CD012244.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"4351_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejmp.2018.01.018","volume":"46","author":"D Kawahara","year":"2018","unstructured":"Kawahara D, Nakano H, Ozawa S, Saito A, Kimura T, Suzuki T, et al. Relative biological effectiveness study of lipiodol based on microdosimetric-kinetic model. Phys Med. 2018;46:89\u201395. https:\/\/doi.org\/10.1016\/j.ejmp.2018.01.018.","journal-title":"Phys Med"},{"issue":"3","key":"4351_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5603\/RPOR.a2022.0067","volume":"27","author":"D Kawahara","year":"2022","unstructured":"Kawahara D, Saito A, Nakano H, Nagata Y. DNA strand breaks based on Monte Carlo simulation in and around the lipiodol with flattening filter and flattening filter-free photon beams. Rep Pract Oncol Radiother. 2022;27(3):392\u2013400. https:\/\/doi.org\/10.5603\/RPOR.a2022.0067.","journal-title":"Rep Pract Oncol Radiother"},{"key":"4351_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.14578","author":"D Kawahara","year":"2024","unstructured":"Kawahara D. Enhancing targeted doses: low-energy photon lipiodol-enhanced radiotherapy (LEPERT) for liver cancer patients. J Appl Clin Med Phys. 2024. https:\/\/doi.org\/10.1002\/acm2.14578.","journal-title":"J Appl Clin Med Phys"},{"issue":"1","key":"4351_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.rpor.2017.12.004","volume":"23","author":"D Kawahara","year":"2018","unstructured":"Kawahara D, Ozawa S, Saito A, Kimura T, Suzuki T, Tsuneda M, et al. Energy spectrum and dose enhancement due to the depth of the Lipiodol position using flattened and unflattened beams. Rep Pract Oncol Radiother. 2018;23(1):50\u20136. https:\/\/doi.org\/10.1016\/j.rpor.2017.12.004.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"5B","key":"4351_CR14","first-page":"4357","volume":"19","author":"S Durand-Fontanier","year":"1999","unstructured":"Durand-Fontanier S, Simon A, Duroux JL, Descottes B, Delage C. Lipiodol ultra-fluid: an antitumor agent-in vitro study. Anticancer Res. 1999;19(5B):4357\u201361.","journal-title":"Anticancer Res"},{"key":"4351_CR15","unstructured":"National Institute of Standards and Technology. X-Ray Mass Attenuation Coefficients - Iodine. Available at: https:\/\/physics.nist.gov\/PhysRefData\/XrayMassCoef\/ElemTab\/z53.html. Accessed December 21, 2025."},{"key":"4351_CR16","unstructured":"Berger MJ, Hubbell JH, Seltzer SM, Chang J, Coursey JS, Sukumar R, et al. XCOM: photon cross sections database. 2010. Available at: https:\/\/www.nist.gov\/pml\/xcom-photon-cross-sections-database. Accessed 21 December 2025."},{"issue":"1","key":"4351_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1118\/1.595378","volume":"10","author":"R Santos Mello","year":"1983","unstructured":"Santos Mello R, Callisen H, Winter J, Kagan AR, Norman A. Radiation dose enhancement in tumors with iodine. Med Phys. 1983;10(1):75\u20138. https:\/\/doi.org\/10.1118\/1.595378.","journal-title":"Med Phys"},{"issue":"2","key":"4351_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0167-8140(87)80170-6","volume":"8","author":"KS Iwamoto","year":"1987","unstructured":"Iwamoto KS, Cochran ST, Winter J, Holburt E, Higashida RT, Norman A. Radiation dose enhancement therapy with iodine in rabbit VX-2 brain tumors. Radiother Oncol. 1987;8(2):161\u201370. https:\/\/doi.org\/10.1016\/s0167-8140(87)80170-6.","journal-title":"Radiother Oncol"},{"issue":"1","key":"4351_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2307\/3575225","volume":"84","author":"H Matsudaira","year":"1980","unstructured":"Matsudaira H, Ueno AM, Furuno I. Iodine contrast medium sensitizes cultured mammalian cells to X rays but not to \u03b3 rays. Radiat Res. 1980;84(1):144. https:\/\/doi.org\/10.2307\/3575225.","journal-title":"Radiat Res"},{"issue":"16","key":"4351_CR20","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1039\/c2nr31227a","volume":"4","author":"KT Butterworth","year":"2012","unstructured":"Butterworth KT, McMahon SJ, Currell FJ, Prise KM. Physical basis and biological mechanisms of gold nanoparticle radiosensitization. Nanoscale. 2012;4(16):4830\u20138. https:\/\/doi.org\/10.1039\/c2nr31227a.","journal-title":"Nanoscale"},{"issue":"9","key":"4351_CR21","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2217\/fon.12.96","volume":"8","author":"L Maggiorella","year":"2012","unstructured":"Maggiorella L, Barouch G, Devaux C, Pottier A, Deutsch E, Bourhis J, et al. Nanoscale radiotherapy with hafnium oxide nanoparticles. Future Oncol. 2012;8(9):1167\u201381. https:\/\/doi.org\/10.2217\/fon.12.96.","journal-title":"Future Oncol"},{"issue":"8","key":"4351_CR22","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/s1470-2045(19)30326-2","volume":"20","author":"S Bonvalot","year":"2019","unstructured":"Bonvalot S, Rutkowski PL, Thariat J, Carr\u00e8re S, Ducassou A, Sunyach M-P, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2\u20133, randomised, controlled trial. Lancet Oncol. 2019;20(8):1148\u201359. https:\/\/doi.org\/10.1016\/s1470-2045(19)30326-2.","journal-title":"Lancet Oncol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-026-04351-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:56:28Z","timestamp":1778248588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-026-04351-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4351"],"URL":"https:\/\/doi.org\/10.1007\/s00270-026-04351-4","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kentaro\u00a0Yamada reports grants and consulting fees from Kaneka\u00a0Medical\u00a0America and GE\u00a0Healthcare, outside the submitted work. Khashayar\u00a0Farsad reports grants from AstraZeneca and W.L.\u00a0Gore; consulting fees from Baylis\u00a0Medical, Inquis, and Neuwave; and is the founder of and holds equity in Auxetics,\u00a0Inc., all outside the submitted work. Kenkichi\u00a0Michimoto, Arianna\u00a0Anoushiravani, Takeshi\u00a0Suzuki, Todd\u00a0Graham, Austin\u00a0Bunker, Andrew\u00a0Bertinetti, Nima\u00a0Nabavizadeh, Rachel\u00a0T.\u00a0Huynh, and Joshua\u00a0M.\u00a0Walker report no other conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict\u00a0of\u00a0interest"}},{"value":"This article does not contain any studies with human participants or animals; therefore, formal ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical\u00a0approval"}},{"value":"For this type of in\u00a0vitro study, informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed\u00a0consent"}},{"value":"For this type of in\u00a0vitro study, consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent\u00a0for\u00a0publication"}}]}}